The metabolic syndrome and the risk of thrombosis

Haematologica

Volumn 92, Issue 3, 2007, Pages 297-299

  Dentali, Francesco ^a   Romualdi, Erica ^a   Ageno, Walter ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABDOMINAL OBESITY; ADIPOSE TISSUE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DYSLIPIDEMIA; EDITORIAL; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERCOAGULABILITY; HYPERINSULINEMIA; INFLAMMATORY DISEASE; METABOLIC SYNDROME X; POPULATION RESEARCH; PUBLIC HEALTH PROBLEM; SYSTOLIC BLOOD PRESSURE; THROMBOSIS; WAIST CIRCUMFERENCE; ANTHROPOMETRY; BLOOD; CASE CONTROL STUDY; COHORT ANALYSIS; FEMALE; MALE; METABOLISM; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OBESITY; PATHOPHYSIOLOGY; PHYSIOLOGY; PREVALENCE; PROSPECTIVE STUDY; RISK FACTOR; SECRETION; THROMBOPHILIA; VASCULAR ENDOTHELIUM;

ADIPONECTIN; ADIPONECTIN, HUMAN; ANGIOTENSIN II; C REACTIVE PROTEIN; CYTOKINE; PLASMINOGEN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ADIPONECTIN; ADIPOSE TISSUE; ANGIOTENSIN II; ANTHROPOMETRY; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CEREBROVASCULAR ACCIDENT; COHORT STUDIES; CYTOKINES; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; OBESITY; PLASMINOGEN; PREVALENCE; PROSPECTIVE STUDIES; RISK FACTORS; THROMBOPHILIA; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 34247578202     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11243     Document Type: Editorial

References (39)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, andTreatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-96.
2. Hill JO, Bessesen D. What to do about the metabolic syndrome? Arch Intern Med 2003;163:395-7.
3. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-52.
4. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. Brussels: IDF 2005. Available at http://www.idf.org/webdata/docs/IDF_Metasyndrome_definition.pdf
5. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome. Prevalence and associated risk factor findings in the US population from the Third National Health and Nutrion Examination Survey, 1988-1994. Arch Intern Med 2003; 163:427-36.
6. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-16.
7. Balkau B, Charles MA, Drivsholm T, Borch-Johnsen K, Wareham N, Yudkin JS, et al; European Group for the Study of Insulin Resistance (EGIR). Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002;28:364-76.
8. Vanhala MJ, Kumpusalo EA, Pitkajarvi TK, Takala JK. Metabolic syndrome' in a middle-aged Finnish population. J Cardiovasc Risk. 1997;4:291-5.
9. McNeill AM, Rosamond WD, Girman CJ, Golden SH, Schmidt MI, East HE, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk In Communities study. Diabetes Care 2005;28:385-90.
10. Schillaci G, Pirro M, Vaudo G, Gemelli F, Marchesi S, Porcellati C, et al. Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol 2004; 43: 1817-22.
11. Milionis HJ, Rizos E, Goudevenos J, Seferiadis K, Mikhailidis DP, Elisaf MS. Components of the metabolic syndrome and risk for first-ever acute ischemic nonembolic stroke in elderly subjects. Stroke 2005;36:1372-6.
12. Koren-Morag N, Goldbourt U, Tanne D. Relation between the metabolic syndrome and ischemic stroke or transient ischemic attack: a prospective cohort study in patients with atherosclerotic cardiovascular disease. Stroke 2005;36:1366-71.
13. Kurl S, Laukkanen JA, Niskanen L, Laaksonen D, Sivenius J, Nyyssonen K, et al. Metabolic syndrome and the risk of stroke in middle-aeed men. Stroke 2006; 37:806-11.
14. Lyon CJ, Law RE, Hsueh WA. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology 2003; 144:2195-200.
15. Blake GJ, Ridker PM: C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol 2003;41:37S-42S.
16. Nickenig G. Should angiotensin II receptor blockers and statins be combined? Circulation 2004;110:1013-20.
17. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both tipoatrophy and obesity. Nat Med 2001;7:941-6.
18. Chen H, Montagnard M, Funahashi T, Shimomura I, Quon MJ. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 2003; 278:45021-6.
19. Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M, et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003;107:671-4.
20. Raynaud E, Perez-Martin A, Brun J, Aissa-Benhaddad A, Fedou C, Mercier J. Relationships between fibrinogen and insulin resistance. Atherosclerosis 2000;150:365-70.
21. Ford ES. The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey. Atherosclerosis 2003;168:351-8.
22. Yudkin JS, Juhan-Vague I, Hawe E, Humphries SE, di Minno G, Margaglione M, et al. Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the HIFMECH study. Metabolism 2004;53:852-7.
23. Duncan BB, Schmidt MI, Chmabless LE, Folsom AR, Carpenter M, Heiss G. Fibrinogen, other putative markers of inflammation, and weight gain in middle-aged adults-the ARIC study. Atherosclerosis Risk in Communities Obes Res 2000;8:279-86.
24. Alessi MC, Bastelica D, Mavri A, Morange P, Berthet B, Grino M, et al. Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation. Arterioscler Thromb Vasc Biol 2003;23:1262-8.
25. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al. Association of non-alcoholic fatty liver disease with insulin resistance. Am J Med 1999;107:450-5.
26. Banfi C, Mussoni L, Ris P, Cattaneo MG, Vicentini L, Battaini F, et al. Very low density lipoprotein-mediated signal transduction and plasminogen activator inhibitor type 1 in cultured HepG2 cells. Circ Res 1999, 85:208-17.
27. Godsland IF, Crook D, Proudler AJ, Stevenson JC. Hemostatic risk factors and insulin sensitivity, regional body fat distribution, and the metabolic syndrome. J Clin Enocrinol Metab 2004;90:190-7.
28. Thomas GN, Chook P, Qiao M, Huang XS, Leong HC, Celermeyer DS, et al. Deleterious impact of "high normal" glucose levels and other metabolic syndrome components on arterial endothelial function and intima-media thickness in apparently healthy Chinese subjects: the CATHAY study. Arterioscler Thromb Vasc Biol 2004; 24:739-43.
29. Trovati M, Mularoni EM, Burzacca S, Ponziani MC, Massucco P, Matiello L. Impaired insulin induced platelet antiaggregating effect in obesity and in obese NIDDM patients. Diabetes 1995;44:1318-22.
30. Doggen CJ, Smith NL, Lemaitre RN, Heckbert SR, Roosendaal FR, Psaty BM. Serum lipid levels and the risk of venous thrombosis. Arterioscler Thromb Vasc Biol 2004;24:1970-5.
31. Englyst NA, Taube JM, Aitman TJ, Baglin TP, Byrne CD. A novel role for CD36 in VLDL-enhanced platelet activation. Diabetes 2003;52:1248-55.
32. Jarvis GE, Atkinson BT, Snell DC, Watson SP. Distinct roles of GPVI and integrin a(2)b(1) in platelet shape change and aggregation induced by different collagens. Br J Pharmacol 2002;137:107-17.
33. Ageno W, Prandoni P, Romualdi E, Ghirarduzzi A, Dentali F, Pesavento R, et al. The metabolic syndrome and the risk of venous thrombosis. A case control study. J Thromb Haemost 2006;4:1914-8.
34. Ay C, Tengler T, Vormittag R, Simanek R, Dorda W, Vukovich T, et al. Venous thromboembolism - a manifestation of the metabolic syndrome. Haematologica 2007;92:373-9.
35. Prandoni P, Bilora F, Marchiori A, Bernardi E, Petrobelli F, Lensing AWA, et al. An association between atherosclerosis andvenous thrombosis. N Engl J Med 2003; 348:1435-41.
36. Becattini C, Agnelli G, Prandoni P, Silingardi M, Salvi R, Taliani MR, et al. A prospective study on cardiovascular events after acute pulmonary embolism. Eur Heart J 2005;26:77-83.
37. Prandoni P, Ghirarduzzi A, Prins MH, Pengo V, Davidson BL, Sorensen H, et al. Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis. J Thromb Haemost 2006;4:1891-6.
38. Reilly MP, Rader DJ. The metabolic syndrome. More than the sum of its parts? Circulation 2003;108:1546-51.
39. Khunti K, Davies M. Metabolic syndrome. Br Med J 2005;11:53-4.